Commercial success and patent validity

Overview
  • In Purdue Pharma L.P. v. Watson Laboratories, Inc., serving as a testifying expert on commercial success as an objective indicator of patent non-obviousness on behalf of plaintiff Purdue alleging patent infringement in connection with certain generic drug manufacturers’ Paragraph IV Abbreviated New Drug Applications (ANDAs) concerning generic versions of Purdue’s Butrans® transdermal opioid pain medication. Provided expert reports and deposition testimony.
  • In Purdue Pharma L.P. v. Depomed, Inc., served as a testifying expert on commercial success as an objective indicator of patent non-obviousness on behalf of Petitioner Purdue’s Inter Partes Review (IPR) challenge to the validity of certain Depomed patents. Provided declaration and deposition testimony.
  • In Janssen Products, L.P. v. Lupin Limited, served as a testifying expert regarding commercial success as a secondary consideration of patent nonobviousness on behalf of plaintiff Janssen alleging patent infringement in connection with Paragraph IV ANDAs concerning generic versions of Janssen’s PREZISTA® HIV treatment prescription drug. Provided expert report and deposition testimony.
  • In First American CoreLogic, Inc. v. Fiserv, Inc., submitted expert reports and testified in federal court involving a patent for estimating residential property values. Assessed the validity of the patent in light of the prior art that included both academic research and industry-based estimation systems and analysis.
  • Retained as testifying expert and submitted two declarations to US Patent Trial and Appeals Board on behalf of a petitioner in a patent infringement case involving methods for optimizing healthcare services management.